Biosimilars/News
Korean biopharma gets support for biosimilars/biobetters
As reported by Narayan Kulkami, Singapore, in BioSpectrum Asia Edition on 18 January 2010, the [South] Korean biopharmaceutical industry continues to get the attention of the global players, mainly because the Korean government in 2009 identified ‘biopharmaceutical and medical equipment’ as one of the future engines for economic growth. The life sciences industry in Korea consists of close to 2000 companies including 580 pharmaceutical companies and 600 biotech companies. (see also Korean biopharma: special programme for biosimilars)
Korean biopharma: special programme for biosimilars
As reported by Narayan Kulkami, Singapore, in BioSpectrum Asia Edition on 18 January 2010, the Korean biopharmaceutical sector gets support for biosimilars and/or biobetters.(see also Korean biopharma gets support for biosimilars/biobetters)
Medarex: With CDA1, CDB1 MAbs better metronidazole or vancomycin treatment against C difficile toxins
New therapies are needed to manage the increasing incidence, severity, and high rate of recurrence of Clostridium difficile infection in which toxins A and B cause pseudomembranous colitis. This is associated with bleeding and a severe form of diarrhoea, which together can lead to perforation of the lower bowel and even death.
Campbell Alliance: how biotech should prepare for biosimilars
In the recently published article ‘Bracing for Biosimilars’ by Kuyler Doyle, Tony Lanzone and Fahti Khosrow-Shahi of management consultancy firm Campbell Alliance, some insight is given into what commercial and reimbursement decision makers for biotechnology companies should be doing to prepare for the arrival of biosimilars.
Minimal 12 years of biologicals data exclusivity required
As reported by Gene Quinn on IPWatchdog.com, for many months we have been hearing about the US government attempts to “reform” health care in the United States.
Teva seeks closer ties with Lonza on biosimilars
Biogenerics is a field that is becoming more and more important to Teva and the company seeks to deepen its existing ties in this area with Swiss company Lonza. Sources inform Globes that Teva President and CEO, Shlomo Yanay, CFO Eyal Desheh, and all the company’s board, flew to Switzerland for two days of meetings intended to extend the collaboration between the two companies.
Pfizer’s biosimilars strategy
“I think it is a good strategy for a large company like Pfizer that wants to be a player in generics”, Ronny Gal, a Sanford C Bernstein Analyst in New York said. “I would be surprised if they weren’t considering biogenerics”.
Dr Stephen Sherwin: Biosimilars pathway with 12 to14 years of biologics exclusivity
BIO SmartBrief Editor Ashley McMaster, corresponded with Ceregene co-Founder/Chairman and BIO Board Chair Dr Stephen Sherwin to get his thoughts on what direction the biotechnology industry is headed in 2010.
Teva submits BLA for biosimilar filgrastim in US
Teva has taken its first step in the US biosimilars market. On 1 December 2009 the company submitted a Biologics License Application (BLA) with the US FDA for XM02, a biosimilar filgrastim for the treatment of severe neutropenia, a blood disorder characterised by an abnormally low number of neutrophils, the most important type of white blood cells in the blood.
Biosimilar EPO, vildagliptin and liraglutide among latest Japanese recommendations
The latest batch of positive product recommendations in Japan includes a biosimilar erythropoietin (EPO) and two novel antidiabetics, Novartis’s DPP-4 inhibitor Equa (vildagliptin) and Novo Nordisk’s GLP-1 analogue Victoza (liraglutide).
